Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin

Human and Experimental Toxicology

Volumn 26, Issue 1, 2007, Pages 19-35

  Kratz, F ^a   Ehling, G ^b   Kauffmann, H M ^b   Unger, C ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

(6 maleimidocaproyl)hydrazone derivative of doxorubicin; Doxorubicin; Human serum albumin; Prodrug; Toxicity

Indexed keywords

(6 MALEIMIDOCAPROYL)HYDRAZONE DERIVATIVE; ADRIMEDAC; ALBUMIN; ANTINEOPLASTIC AGENT; DOXORUBICIN; HYDRAZONE DERIVATIVE; PRODRUG; TROPICAMIDE; UNCLASSIFIED DRUG;

AGITATION; ALOPECIA; ANIMAL EXPERIMENT; ARTICLE; ATRIOVENTRICULAR BLOCK; CONTROLLED STUDY; DERMATITIS; DOG; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; ERYTHEMA; FECES INCONTINENCE; FEMALE; HISTOPATHOLOGY; LD 50; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MOTOR DYSFUNCTION; MOUSE; MUSCLE ATROPHY; NEUROTOXICITY; NONHUMAN; OLIGOSPERMIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; SALIVATION; SINGLE DRUG DOSE; SINUS TACHYCARDIA; SKELETAL MUSCLE; SKIN SWELLING; SPRAGUE DAWLEY RAT; TESTIS ATROPHY; TISSUE NECROSIS; TREMOR;

ACUTE TOXICITY TESTS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOGS; DOXORUBICIN; FEMALE; HYDRAZONES; LETHAL DOSE 50; MALE; MICE; MICE, INBRED STRAINS; PRODRUGS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN; TOXICITY TESTS, CHRONIC;

ANIMALIA; CANIS FAMILIARIS; MURINAE; MUS; RATTUS;

EID: 33847029969     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1177/0960327107073825     Document Type: Article

References (27)

1. Gianni L, Grasselli G, Cresta S, Locatelli A, Vigano L, Minotti G. Anthracyclines. Cancer Chemother Biol Response Modif 2003; 21: 29-40.
2. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229.
3. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339: 900-905.
4. Kratz F, Mueller-Driver R, Hofmann I, Drevs J, Unger C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J Med Chem 2000; 43: 1253-56.
5. Kratz F, Warnecke A, Scheuermann K, Stockmar C, Schwab J, Lazar P, Drückes P, Esser N, Drevs J, Rognan D, Bissantz C, Hinderling C, Folkers G, Fichtner I, Unger C. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem 2002; 45: 5523-33.
6. Mansour AM, Drevs J, Esser N, Hamada FM, Badary OA, et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res 2003; 63: 4062-66.
7. Warnecke A, Kratz F. Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy. Bioconjugate Chem 2003; 14: 377-87.
8. Kratz F, Beyer U. Serum proteins as drug carriers of anticancer agents: a review. Drug Deliv 1998; 5: 281-99.
9. Maeda H, Wu J, Sawa T, Matsumura Y, Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Rel 2000; 65: 271-84.
10. Carter DC, Ho JX. Structure of serum albumin. Adv Prot Chem 1994; 45: 153-203.
11. Willner D, Trail PA, Hofstead SJ, King HD, Lasch SJ, Braslawsky GR, Greenfield RS, Kaneko T, Firestone RA. (6-Maleimidocaproyl)hydrazone of doxorubicin - a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconj Chem 1993; 4: 521-27.
12. Lebrecht D, Geist A, Ketelsen U, Haberstroh J, Setzer B, Kratz F, Walker U. The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. Int J Cancer 2006 (in press).
13. Unger C, Medinger M, Steinbild S, Drevs J, Häring B, Kratz F, Mross K. Phase I dose-escalation and pharmacokinetic (PK) study of a (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH) in patients with advanced cancers. German Cancer Congress, Berlin, 2006.
14. Bertazzoli C, Rovero C, Ballerini L, Lux B, Balconi F, Antongiovanni V, Magrini U. Experimental systemic toxicology of 4′-epidoxorubicin, a new, less cardiotoxic anthracycline antitumor agent. Toxicol Appl Pharmacol 1985; 79: 412-22.
15. Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, Maggi CA, Capranico G, Animati F. Anthracyclines: selected new developments. Curr Med Chem Anti-Cancer Agents 2001; 1: 113-30.
16. Monneret C. Recent developments in the field of antitumour anthracyclines. Eur J Med Chem 2001; 36: 483-93.
17. Rooseboom M, Commandeur JN, Vermeulen NP. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 2004; 56: 53-102.
18. Arcamone F, Animati F, Capranico G, Lombardi P, Pratesi G, et al. New developments in antitumor anthracyclines. Pharmacol Ther 1997; 76: 117-24.
19. Arcamone FM. From the pigments of the actinomycetes to third generation antitumor anthracyclines. Biochimie 1998; 80: 201-206.
20. Giannini G. Fluorinated anthracyclines: synthesis and biological activity. Curr Med Chem - Anti-Cancer Agents 2002; 9: 687-712.
21. Suarato A, Angelucci F, Geroni C. Ring-B modified anthracyclines. Curr Pharm Design 1999; 5: 217-27.
22. Kratz F, Warnecke A, Schmid B, Chung D, Gitzel M. Prodrugs of anthracyclines in cancer chemotherapy. Curr Med Chem - Anti-Cancer Agents 2006; 13: 447-523.
23. Haag R, Kratz F. Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl 2006; 45: 1198-215.
24. Cho ES. Toxic effects of adriamycin on the ganglia of the peripherial nervous system: a neuropathological study. J Neuropathol Exp Neurol 1977; 36: 907-15.
25. Jortner BS, Cho ES. Neurotoxicity of adrimycin in rats: a low-dose effect. Cancer Treat Rep 1980; 64: 257-61.
26. Bristow MR, Sageman WS, Scott RH, Billingham ME, Bowden RE, Kernoff RS, Snidow GH, Daniels JR. Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol 1980; 2: 487-515.
27. Dorr RT, Von Hoff DD, eds. Cancer chemotheraphy handbook, 2nd ed. Norwalk: Appleton & Lange, 1994.